or
forgot password

    • cancer clinical trials in huntersville, NC

    • A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Non-Small Cell Lung Cancer
    Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Prostate Cancer, Neoplasm Metastasis
    Isolation and Culture of Circulating Tumor Cells From Peripheral Blood
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Metastatic Cancer
    A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Metastatic Castration-resistant Prostrate Cancer (mCRPC), Renal Cell Carcinoma (RCC), Metastatic Melanoma (MEL), Non-small Cell Lung Cancer (NSCLC)
    A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
    Carolina BioOncology Institute, PLLC
    Huntersville, North Carolina 28078
    Advanced Malignancies
    A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
    University Medical Associates
    Huntersville, North Carolina 28078
    Overactive Bladder
    A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    Presbyterian Hospital Huntersville
    Huntersville, North Carolina 28078
    Advanced Prostate Cancer, Prostatic Neoplasms
    Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Cancer
    Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Kidney Cancer
    3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
    Boehringer Ingelheim Investigational Site
    Huntersville, North Carolina
    HIV Infections
    A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
    Carolina BioOncology Institute, PLLC
    Huntersville, North Carolina 28078
    Hodgkin's Disease
    A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer
    Site Reference ID/Investigator# 2242
    Huntersville, North Carolina 28078
    Lung Cancer, NSCLC, Non-Small-Cell Lung Cancer
    MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Lymphoma, Large-Cell
    A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
    Carolina BioOncology Institute, PLLC
    Huntersville, North Carolina 28078
    Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
    Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer
    A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
    Carolina BioOncology Institute Cancer
    Huntersville, North Carolina 28078
    Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer
    Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
    Carolina BioOncology Institute
    Huntersville, North Carolina 28078
    Lung Cancer - Non Small Cell